Many recombinant viral vectors for expression of ectopic antigens mimic a natural infection and can induce a robust immune response against certain pathogens and tumors. Host-restricted poxviruses and ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

Osmolality is a well-established parameter for upstream bioprocessing, formulation, analytical development and QC applications throughout the manufacturing of biological drugs. A recent publication ...

Continuous bioprocessing has emerged as a transformative approach in modern biomanufacturing, where integrated upstream and downstream operations enable uninterrupted production of biotherapeutics.

The pursuit of Biosimilars, Antibody-Drug Conjugates and New Processing Technologies will set the trend for biomanufacturing in 2013; so says research from the industry's leading conference and ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...